{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:11:01Z","timestamp":1778757061953,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":196,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.6061\/clinics\/2021\/e2837","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T08:56:22Z","timestamp":1626252982000},"page":"e2837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Germline and Somatic mutations in postmenopausal breast cancer patients"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-1593","authenticated-orcid":false,"given":"Tauana Rodrigues","family":"Nagy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0937-2391","authenticated-orcid":false,"given":"Simone","family":"Maistro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-7400","authenticated-orcid":false,"given":"Giselly","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-8222","authenticated-orcid":false,"given":"Maria Lucia Hirata","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-2808","authenticated-orcid":false,"given":"Glaucia Fernanda de Lima","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-9359","authenticated-orcid":false,"given":"Nelson","family":"Gaburo-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-920X","authenticated-orcid":false,"given":"Lucas Augusto Moyses","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-6669","authenticated-orcid":false,"given":"Ana Carolina Ribeiro Chaves de","family":"Gouv\u00eaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-9747","authenticated-orcid":false,"given":"Maria del Pilar Estevez","family":"Diz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-3013","authenticated-orcid":false,"given":"Luiz Antonio Senna","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-8052","authenticated-orcid":false,"given":"Maria Aparecida Azevedo Koike","family":"Folgueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.6061\/clinics\/2021\/e2837_bib1","first-page":"439","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.6061\/clinics\/2021\/e2837_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/jnci\/djz106","article-title":"Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years","volume":"111","author":"Ward","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2837_bib3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk Factors and Preventions of Breast Cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int J Biol Sci"},{"issue":"23","key":"10.6061\/clinics\/2021\/e2837_bib4","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.6061\/clinics\/2021\/e2837_bib5","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","article-title":"Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years","volume":"66","author":"Malone","year":"2006","journal-title":"Cancer Res"},{"issue":"7239","key":"10.6061\/clinics\/2021\/e2837_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2837_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1590\/1806-9282.61.05.474","article-title":"Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis","volume":"61","author":"Encinas","year":"2015","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.6061\/clinics\/2021\/e2837_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","article-title":"PI3K signaling in cancer: beyond AKT","volume":"45","author":"Lien","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2837_bib9","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-04-4114","article-title":"Functional analysis of PIK3CA gene mutations in human colorectal cancer","volume":"65","author":"Ikenoue","year":"2005","journal-title":"Cancer Res"},{"issue":"23","key":"10.6061\/clinics\/2021\/e2837_bib10","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"issue":"2 Pt 1","key":"10.6061\/clinics\/2021\/e2837_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-06-0267","article-title":"Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women","volume":"13","author":"Maruyama","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2837_bib12","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/bcr3113","article-title":"PIK3CA mutation impact on survival in breast cancer patients and in ER\u03b1, PR and ERBB2-based subgroups","volume":"14","author":"Cizkova","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2837_bib13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.6061\/clinics\/2012(11)11","article-title":"PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients","volume":"67","author":"Mangone","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2837_bib14","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1984","article-title":"PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer","volume":"10","author":"Liedtke","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"16","key":"10.6061\/clinics\/2021\/e2837_bib15","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","article-title":"PIK3CA mutation associates with improved outcome in breast cancer","volume":"15","author":"Kalinsky","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.6061\/clinics\/2021\/e2837_bib16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/jnci\/djt121","article-title":"Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer","volume":"105","author":"Loi","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2837_bib17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2837_bib18","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.18632\/aging.102783","article-title":"Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer","volume":"12","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2837_bib19","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/bcr3463","article-title":"PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer","volume":"15","author":"Deb","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"31","key":"10.6061\/clinics\/2021\/e2837_bib20","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2837_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","article-title":"Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling","volume":"18","author":"Azim","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.6061\/clinics\/2021\/e2837_bib22","doi-asserted-by":"crossref","first-page":"22460","DOI":"10.18632\/oncotarget.25123","article-title":"Somatic mutations in early onset luminal breast cancer","volume":"9","author":"Encinas","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2837_bib23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1186\/s12885-016-2966-x","article-title":"Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil","volume":"16","author":"Maistro","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.6061\/clinics\/2021\/e2837_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS Recommendations for the Description of Sequence Variants: 2016 Update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2837_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"6","key":"10.6061\/clinics\/2021\/e2837_bib26","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1007\/s13277-016-4924-2","article-title":"Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer","volume":"37","author":"Dirican","year":"2016","journal-title":"Tumour Biol"},{"issue":"10","key":"10.6061\/clinics\/2021\/e2837_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2020.0229","article-title":"Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer","volume":"323","author":"Kurian","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2837_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27315-2","article-title":"The germline mutational landscape of BRCA1 and BRCA2 in Brazil","volume":"8","author":"Palmero","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.6061\/clinics\/2021\/e2837_bib29","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.6061\/clinics\/2021\/e2837_bib30","article-title":"Detection of inherited mutations in Brazilian breast cancer patients using multi-gene panel testing. In: 2018 American Society of Clinical Oncology Annual Meeting, 2018, Chicago","volume":"36","author":"Guindalini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2837_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057581","article-title":"Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil","volume":"8","author":"Carraro","year":"2013","journal-title":"PLoS One"},{"issue":"49","key":"10.6061\/clinics\/2021\/e2837_bib32","doi-asserted-by":"crossref","first-page":"80465","DOI":"10.18632\/oncotarget.12610","article-title":"Prevalence of BRCA1\/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry","volume":"7","author":"Fernandes","year":"2016","journal-title":"Oncotarget"},{"key":"10.6061\/clinics\/2021\/e2837_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.11606\/S1518-8787.2018052000643","article-title":"Cost effectiveness of the cancer prevention program for carriers of the BRCA1\/2 mutation","volume":"52","author":"Ramos","year":"2018","journal-title":"Rev Saude Publica"},{"issue":"7","key":"10.6061\/clinics\/2021\/e2837_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071929","article-title":"Economic Evaluation of Population-Based BRCA1\/BRCA2 Mutation Testing across Multiple Countries and Health Systems","volume":"12","author":"Manchanda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2837_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06581-8","article-title":"Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls","volume":"9","author":"Momozawa","year":"2018","journal-title":"Nat Commun"},{"issue":"20","key":"10.6061\/clinics\/2021\/e2837_bib36","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","article-title":"Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients","volume":"23","author":"Sun","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2837_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Hum Mutat"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2837_bib38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.6061\/clinics\/2021\/e2837_bib39","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1073\/pnas.0701005104","article-title":"Rare cancer-specific mutations in PIK3CA show gain of function","volume":"104","author":"Gymnopoulos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6466","key":"10.6061\/clinics\/2021\/e2837_bib40","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2837_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4161\/cbt.5.5.2656","article-title":"Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese","volume":"5","author":"Liang","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2837_bib42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.hemonc.2014.09.007","article-title":"PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers","volume":"7","author":"Castaneda","year":"2014","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2837_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgeb.2017.10.002","article-title":"The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer","volume":"16","author":"Desriani","year":"2018","journal-title":"J Genet Eng Biotechnol"},{"issue":"10","key":"10.6061\/clinics\/2021\/e2837_bib44","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:04:21Z","timestamp":1761721461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222001715"},"secondary":[{"URL":"https:\/\/www.scielo.br\/j\/clin\/a\/hqrFTX4W3rhx6hGyL7ngm5w\/?lang=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8266163\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/germline-and-somatic-mutations-in-postmenopausal-breast-cancer-patients\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":44,"alternative-id":["S1807593222001715"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e2837","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline and Somatic mutations in postmenopausal breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e2837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e2837"}}